Characterization of Adaptive Immune Responses to Oropouche Virus (OROV) Infection (OROV-IMM)
Oropouche virus (OROV), a re-emerging South American arbovirus causing dengue-like fever and occasional neurological complications, is expanding its circulation towards more densely populated areas in French Guiana, as evidenced by recent cases near Cayenne in 2026. While animal models indicate that B cell-mediated humoral immunity is critical for viral control, the human antibody response to OROV remains poorly characterized. Despite WHO-led international research efforts, there is currently no vaccine, antiviral treatment, or described human monoclonal antibody against OROV - a major gap that hinders therapeutic and vaccine development. Identifying human neutralizing monoclonal antibodies could offer a promising therapeutic option, particularly for vulnerable populations such as pregnant women.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The goal of this project is to characterize the adaptive immune response to OROV infection during the convalescent phase.
The study is based on three complementary populations: (1) 17 adults with confirmed past OROV infection (2020) who will be recontacted for follow-up sampling; (2) 50 adults recruited prospectively from a village with ∼80% seroprevalence, aiming to include at least 20 seropositive individuals for robust analysis of antigen-specific B and T cell responses; and (3) an exploratory cohort of 1 to 10 newly confirmed OROV cases identified during the study period in the Cayenne region, enrolled during the convalescent phase (≥1 month post-diagnosis) to complement the immunological analyses conducted in the first two populations.
A 20 ml blood sample is collected, along with data collection (mainly health data), at the time of enrollment.
The study involves: (1) confirming past OROV infection by detecting OROV-specific polyclonal antibodies in plasma; and (2) characterizing OROV-specific B and T cell responses. Key methodological steps include: isolation of OROV-specific B cells by flow cytometry followed by single-cell culture and stimulation to generate human monoclonal antibodies; screening of secreted mAbs against OROV antigens combined with VDJ sequencing to characterize immunoglobulin repertoires; and structural characterization of neutralizing mAbs using cryo-electron microscopy and nano-imaging to identify conserved epitopes.
Tipo de estudo
Inscrição (Estimado)
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
The study population lives in French Guiana in 3 different areas (Saül, Trois Sauts, and Cayenne and its surroundings), and eligible individuals (Populations 1 and 3) or those residing in a high-seroprevalence geographic area (Population 2) were identified by the National Reference Center (CNR) for Arboviruses at the Institut Pasteur of French Guiana (IPG) as part of arbovirus virological surveillance in French Guiana.
Descrição
Inclusion Criteria:
For all:
- Adults (≥18 years old)
- Willingness to participate in the study after explanation and signing of the informed consent form
Study population 1:
- Presenting a laboratory-confirmed OROV infection, defined by a positive real-time RT-PCR and/or positive seroneutralization performed as part of the management of and response to the 2020 OROV epidemic in Saül.
Study population 2:
- Residing in Trois-Sauts for at least 5 years
Study population 3:
- Presenting a laboratory-confirmed OROV infection, defined by a positive real-time RT-PCR and/or positive seroneutralization, identified in the Cayenne area and surrounding localities during the study period, as part of the surveillance activities of the CNR for Arboviruses (IPG).
Exclusion Criteria:
For all:
- Pregnant women.
- Individuals presenting with severe chronic pathologies (notably active cancer, primary or secondary immunodeficiency, immunosuppressive treatment, HIV infection, or autoimmune diseases), according to the information declared by the participants.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: OTHER
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
adults with confirmed past OROV infection (2020) recruited from Saül
|
A 20-ml blood sample |
|
adults recruited from Trois-Sauts with ∼80% seroprevalence
|
A 20-ml blood sample |
|
newly confirmed OROV cases identified during the study period in the Cayenne region
|
A 20-ml blood sample |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Characterization of the adaptive immune response to OROV infection during the convalescent phase.
Prazo: 12 months
|
OROV-specific polyclonal antibodies will be detected in participants' plasma to confirm prior infection. |
12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Isolate OROV-specific B cells (recognizing the Gn_Gc antigenic complex) and generate human monoclonal antibodies by single B cell culture.
Prazo: 12 months
|
Isolation of OROV-specific B cells by flow cytometry, followed by culture and stimulation of single B cells to generate and identify human monoclonal antibodies specific to OROV. |
12 months
|
|
Screening of secreted mAbs using OROV antigens and VDJ sequencing to characterize immunoglobulin repertoires.
Prazo: 12 months
|
secreted mAbs using OROV antigens and VDJ sequencing will be screened to characterize immunoglobulin repertoires. |
12 months
|
|
Structural characterization of neutralizing mAbs by cryo-EM and nano-imaging to identify conserved epitopes.
Prazo: 12 months
|
cryo-EM and nano-imaging will be performed on neutralizing mAbs to characterize structurally the mAbs |
12 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2026-047_OROV-IMM
- 2026-A01467-44 (Outro identificador: ID-RCB)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .